Savient visits FDA re Krystexxa manufacturing changes; Schering Plough plans long goodbye for 160 plant workers;

> Savient Pharmaceuticals is on the FDA's calendar today following last year's rejection of gout treatment Krystexxa due to concerns over manufacturing changes. Story

> Schering Plough will eliminate 160 jobs on a voluntary basis over three years at its west Cork manufacturing plant. Article 

> Rio de Janeiro drugmaker Mantecorp has adopted Mitsubishi automation controllers and the open-technology CC-Link industrial communication network in a renovation of two facilities totaling 350,000 square meters. News

> DHL has teamed with frozen transport and packaging systems provider CryoPort to offer drugmakers speedy access to the latter's CryoPort Express Shipper and preferred DHL shipping rates. CryoPort release

> Advaxis has begun a manufacturing program for clinical quantities of human-grade ADXS31-164, a live Listeria vaccine that targets Her2 tumors. Advaxis release

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.